TNF Inhibitor denied due to quantity / dose limits by Florida Blue?

Florida Blue uses Prime Therapeutics or CVS Caremark depending on plan line. Step therapy through preferred biosimilar.

FL Statute 627.42393 limits step therapy when prior failure documented. Demand peer-to-peer review. Cite continuity-of-care for stable patients.

## Why Florida Blue Applies Quantity Limits to TNF Inhibitors

TNF inhibitors are specialty-tier biologics dispensed in manufacturer-specific packaging (prefilled syringes, autoinjectors, or infusion vials). Florida Blue's quantity limits for this drug class are designed to align dispensing quantities with the dosing regimen described in the FDA-approved prescribing label. A denial for "quantity limits" typically means your prescription requested more units, more frequent fills, or a different package size than the plan's standard limit allows. This can happen during dose escalation, a loading-dose phase, or when a prescriber adjusts the regimen.

## Why This Denial Is Often Appealable

FDA-approved prescribing information for TNF inhibitors includes defined dosing regimens — some conditions have induction/loading doses that differ from maintenance doses, and some patients require adjustments based on clinical response. If the quantity prescribed aligns with a recognized dosing schedule in the label or in applicable specialty-society guidance, the prescriber can document that the request is medically necessary and consistent with approved use. Florida Blue's own medical policy must be consistent with the label; where it is more restrictive, that gap is the basis of appeal.

## Your Federal Appeal Rights

• Internal appeal: File within the timeframe on your denial notice. Pre-service non-urgent decisions are due within 30 days; post-service within 60 days.
• External review (ACA §2719): After a final internal denial, request IRO external review within approximately four months. The IRO decision is binding.
• Expedited review: Request if the standard timeline would meaningfully harm your health; response is typically within 72 hours.
• ERISA §503: Employer-plan members have a right to review all documents used in the denial and to submit additional evidence.

## Documentation to Gather

1. Current FDA-approved prescribing information — the full label for the specific TNF inhibitor, with the applicable dosing regimen and any provisions for dose adjustment, highlighted. 2. Prescriber letter explaining the quantity request — a letter from the treating specialist detailing why the requested quantity is medically necessary, citing the relevant section of the prescribing label or specialty-society dosing guidance. 3. Clinical records supporting dose adjustment — chart notes documenting disease activity, response to prior dosing, and the clinical rationale for any escalation. 4. Prior dispensing history — pharmacy records showing the patient's dispensing history to establish continuity and context for the current request.

## Criteria-Mapping Strategy

Locate Florida Blue's published quantity-limit policy for this TNF inhibitor (available in their drug list or medical policies). For each stated limit, compare the limit to the dosing parameters in the FDA prescribing label. Where the label permits or requires higher quantities in specific clinical scenarios, annotate those sections and pair them with the chart documentation showing your patient is in exactly that scenario. A prescriber attestation that the requested quantity reflects standard-of-care dosing — rather than an exceptional or experimental regimen — significantly strengthens the appeal.